1-[2-(4-Methyl-2-nitrophenoxy)ethyl]piperidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[2-(4-Methyl-2-nitrophenoxy)ethyl]piperidine
• 化学式: C14H20N2O3
• 分子量: 264.32
• InChiKey: OECPZHSNPGJSFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  58.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• AURORA INHIBITOR
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2036894A1

  公开（公告）日：2009-03-18

  The present invention provides an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof, an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (Ia) [wherein R2 represents CONR4aR4b (wherein R4a and R4b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like, or R4a and R4b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, and R3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof, and the like.

  本发明提供了一种Aurora抑制剂，其作为活性成分包括由式(I)代表的吲唑衍生物(其中R1代表取代或未取代的芳基或取代或未取代的杂环基团)或其药学上可接受的盐，Aurora抑制剂作为活性成分包括式(Ia)代表的吲唑衍生物[其中 R2 代表 CONR4aR4b（其中 R4a 和 R4b 可以相同或不同，且各自代表氢原子、取代或未取代的低级烷基或类似物，或 R4a 和 R4b 与相邻的氮原子结合在一起形成取代或未取代的杂环基团）或类似物，R3 代表氢原子、取代或未取代的低级烷基或类似物]或其药学上可接受的盐，以及类似物。
• PHARMACEUTICAL COMPOSITION
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：EP2133095A1

  公开（公告）日：2009-12-16

  The present invention provides a pharmaceutical composition comprising a combination of an Flt-3 inhibitor and at least one compound, the said pharmaceutical composition wherein an Flt-3 inhibitor is an indazole derivative represented by Formula (I) (wherein R1 represents suctituted or unsubstituted aryl, or the like) or a pharmaceutically acceptable salt thereof, the said pharmaceutical composition wherein an Flt-3 inhibitor is a pyrimidine derivative represented by Formula (II) [wherein -X-Y-Z- represents -O-CR17=N- (wherein R17 represents a hydrogen atom, lower alkyl, or the like), R15 represents -NR22aR22b (wherein R22a and R22b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), and R16 represents -NR24aR24b (wherein R24a and R24b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like] or a pharmaceutically acceptable salt thereof, or the like.

  本发明提供了一种药物组合物，该药物组合物由一种 Flt-3 抑制剂和至少一种化合物组合而成，其中 Flt-3 抑制剂是由式（I）表示的吲唑衍生物 (其中 R1 代表取代或未取代的芳基或类似物）或其药学上可接受的盐，所述药物组合物中 Flt-3 抑制剂是由式 (II) 代表的嘧啶衍生物 [其中 -X-Y-Z- 代表 -O-CR17=N- （其中 R17 代表氢原子、低级烷基或类似物），R15 代表 -NR22aR22b （其中 R22a 和 R22b 可以相同或不同，且各自代表氢原子、取代或未取代的低级烷基、或类似物），以及 R16 代表-NR24aR24b（其中 R24a 和 R24b 可以相同或不同，且各自代表氢原子、取代或未取代的低级烷基或类似物），或其药学上可接受的盐，或类似物]。
• AURORA INHIBITORS
  申请人：Shiotsu Yukimasa

  公开号：US20090209537A1

  公开（公告）日：2009-08-20

  The present invention provides an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof, an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (Ia) [wherein R 2 represents CONR 4a R 4b (wherein R 4a and R 4b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like, or R 4a and R 4b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, and R 3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof, and the like.
• Ab1 KINASE INHIBITORS
  申请人：Shiotsu Yukimasa

  公开号：US20120329794A1

  公开（公告）日：2012-12-27

  The present invention provides an Abelson kinase (Abl kinase) inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R 1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof, an Abl kinase inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (Ia) [wherein R 2 represents CONR 4a R 4b (wherein R 4a and R 4b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like, or R 4a and R 4b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, and R 3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof, and the like.